Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: 993racer who wrote (2866)	5/25/1998 11:38:00 AM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Here is an summary of an article on PFE from today's The Financial Times. This will probably be "The Street's" reaction on Tuesday. BigKNY3 "What goes up must come down. This holds even for Pfizer's remarkable share price, which has been pumped up by the hugely successful launch of its Viagra impotence treatment. In fact, Friday's 3 per cent drop in Pfizer's stock -- after a gain of 45 per cent this year -- was, rightly, a rather modest reaction to news that Viagra may have been a factor in the deaths of six people. While tragic, these deaths on their own do not look statistically significant. After all, Viagra has already been taken by over 1m people. Pfizer has taken pains to point out that it should not be taken in conjunction with certain heart medicines -- but perhaps some patients did so. Unfortunately, this is the kind of lifestyle drug that people will try without seeking proper medical advice. That, of course, is also what drives its unprecedented success. With no palatable alternatives, many people will be prepared to run some risk in return for what they consider to be quite tangible benefits. Unless further problems emerge, it seems too early to pare back sales expectations for Viagra of $2bn-$4bn by 2002. Investors should also remember that Pfizer has one of the broadest and most promising drug pipelines in the industry. While the hype surrounding Viagra may have been overdone, the group is preparing to launch an anti-arthritis treatment that could become its next blockbuster. "